ALK and non-small cell lung carcinoma: On the basis of rolling substudy availability, inclusion criteria, and patient comorbidities, 10 (40%) of the 25 patients with GC (ERBB2, n = 6; MET, n = 1; FGFR2, n = 1; and PIK3CA, n = 2) and 17 (50%) of the 34 patients with NSCLC (EGFR, n = 7; EGFRT790M, n = 7; and ALK, n = 1) with prespecified GTs were matched to a molecularly targeted therapy (Tables 2 and 3).